Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: Suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071

Breast Cancer Research and Treatment

Volumn 146, Issue 1, 2014, Pages 51-62

  Liang, Yayun ^a,b   Besch Williford, Cynthia ^c   Aebi, Johannes D ^d   Mafuvadze, Benford ^a,b   Cook, Matthew T ^a,b   Zou, Xiaoqin ^a,b   Hyder, Salman M ^a,b  

^a UNIVERSITY OF MISSOURI   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c IDDEX RADIL   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Breast cancer; Cholesterol biosynthesis inhibitors; Estrogen receptor; Tumor progression

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUINDOSTATIN; LYASE; OXIDOSQUALENE CYCLASE; RO 48 8071; SIMVASTATIN; SMALL INTERFERING RNA; SULFORHODAMINE B; UNCLASSIFIED DRUG; [4' [6 (ALLYLMETHYLAMINO)HEXYLOXY] 4 BROMO 2' FLUOROBENZOPHENONE FUMARATE]; BENZOPHENONE DERIVATIVE; CHOLESTEROL; LANOSTEROL SYNTHASE; MUTASE; RO 48-8071;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER GROWTH; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; IC50; METABOLISM; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPHENONES; BIOSYNTHETIC PATHWAYS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; INTRAMOLECULAR TRANSFERASES; MICE;

EID: 84903691937     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-2996-5     Document Type: Article

References (50)

1. D'Abreo N, Hindenburg AA (2013) Sex hormone receptors in breast cancer. Vitam Horm 93:99-1331
2. Cordera F, Jordan VC (2006) Steroid receptors and their role in the biology and control of breast cancer growth. Semin Oncol 33:631-641 (Pubitemid 44834535)
3. White R, Parker MG (1998) Molecular mechanisms of steroid hormone action. Endocr Relat Cancer 5:1-14 (Pubitemid 28168185)
4. Pasqualini JR, Katzenellenbogen BS (eds) (1996) Hormonedependent cancer. Marcel Dekker Inc., New York
5. Seeger H, Wallwiener D, Mueck AO (2008) Effects of estradiol and progestogens on tumor-necrosis factor-alpha-induced changes of biochemical markers for breast cancer growth and metastasis. Gynecol Endocrinol 24:576-579
6. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or Progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6:1076-1087
7. Harrell JC, Dye WW, Allred DC et al (2006) Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. Cancer Res 66:9308-9315 (Pubitemid 44521153)
8. Hyder SM (2006) Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat Cancer 13:667-687
9. Bailey ST, Shin H, Westerling T, Liu XS, Brown M (2012) Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA 109:18060-18065
10. Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15:3266-3284 (Pubitemid 38850122)
11. Schairer C, Lubin J, Troisi R et al (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491 (Pubitemid 30062864)
12. Li CI, Malone KE, Porter PL et al (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289:3254-3263 (Pubitemid 37430078)
13. Chlebowski RT, Hendrix SL, Langer RD et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253 (Pubitemid 37430077)
14. Ross RK, Paganini-Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92:328-332 (Pubitemid 30117736)
15. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631-643
16. Hiscox S, Morgan L, Green TP (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97:263-274 (Pubitemid 43945756)
17. Bulun SE, Simpson ER (2008) Aromatase expression in women's cancers. Adv Exp Med Biol 630:112-132
18. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, Umetani M, Geradts J, McDonnell DP (2013) 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 342:1094-1098
19. Wu Q, Ishikawa T, Sirianni R et al (2013) 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep 5:637-645
20. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63:255-267
21. Charlton-Menys V, Durrington PN (2007) Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 67:11-16 (Pubitemid 46105084)
22. Staedler D, Chapuis-Bernasconi C, Dehmlow H et al (2012) Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem 55:4990-5002
23. Thoma R, Schulz-Gasch T, D'Arcy B et al (2004) Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature 432:118-122 (Pubitemid 39490838)
24. Grinter SZ, Liang Y, Huang SY, Hyder SM, Zou X (2011) An inverse docking approach for identifying new potential anti-cancer targets. J Mol Graph Model 29:795-799
25. Treeck O, Lattrich C, Springwald A, Ortmann O (2010) Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat 120:557-565
26. Paruthiyil S, Parmar H, Kerekatte V et al (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428 (Pubitemid 38114127)
27. Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases-a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396:63-66
28. Deroo BJ, Buensuceso AV (2010) Minireview: estrogen receptorbeta: mechanistic insights from recent studies. Mol Endocrinol 24:1703-1714
29. Hartman J, Lindberg K, Morani A et al (2006) Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 66:11207-11213 (Pubitemid 46009948)
30. Dehmlow H, Aebi JD, Jolidon S et al (2003) Synthesis and structure-activity studies of novel orally active non-terpenoic 2,3-oxidosqualene cyclase inhibitors. J Med Chem 46:3354-3370 (Pubitemid 36842420)
31. Liang Y, Besch-Williford C, Benakanakere I, Hyder SM (2007) Re-activation of p53 pathway inhibits growth of hormonedependent human breast cancer cells in vitro and in vivo. Int J Oncol 31:777-784
32. Liang Y, Brekken RA, Hyder SM (2006) VEGF induces proliferation of breast cancer cells and counteracts the anti-proliferative activity of anti-hormones. Endocr Relat Cancer 13:905-919 (Pubitemid 44763266)
33. Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM (2011) Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. Breast Cancer Res Treat 125:407-420
34. Mafuvadze B, Benakanakere I, López Pérez FR, Besch-Williford C, Ellersieck MR, Hyder SM (2011) Apigenin prevents development of medroxyprogesterone acetate-accelerated 7,12-dimethylbenz (a)anthracene-induced mammary tumors in Sprague-Dawley rats. Cancer Prev Res 4:1316-1324
35. Fan M, Bigsby RM, Nephew KP (2003) The NEDD8 pathway is required for proteasome- mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol 17:356-365 (Pubitemid 36315630)
36. Yeh WL, Shioda K, Coser KR, Rivizzigno D, McSweeney KR, Shioda T (2013) Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor a protein in MCF-7 cells require the CSK c-Src tyrosine kinase. PLoS ONE 8:e60889
37. Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA (2004) Estrogen receptor beta inhibits 17beta-estra-diol- stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci USA 101:1566-1571 (Pubitemid 38236167)
38. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L et al (1992) HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605
39. Agrup M, Stål O, Olsen K, Wingren S (2000) C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63:23-29
40. Nawaz Z, Lonard DM, Dennis AP et al (1999) Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862 (Pubitemid 29117832)
41. Robertson JF (2001) ICI 182,780 (Fulvestrant)-the first oestrogen receptor down-regulator - current clinical data. Br J Cancer 85(Suppl 2):11-14
42. Wardell SE, Marks JR, McDonnell DP (2011) The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem Pharmacol 82:122-130
43. Gallagher A, Chambers TJ, Tobias JH (1993) The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133:2787-2791 (Pubitemid 24000737)
44. Sotoca AM, van den Berg H, Vervoort J, van der Saag P, Ström A, Gustafsson JA, Rietjens I, Murk AJ (2008) Influence of cellular ERalpha/ERbeta ratio on the ERalpha-agonist induced proliferation of human T47D breast cancer cells. Toxicol Sci 105:303-311
45. Lindberg MK, Movérare S, Skrtic S et al (2003) Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ER-alpha and ERbeta in mice. Mol Endocrinol 17:203-208 (Pubitemid 36187395)
46. Williams C, Edvardsson K, Lewandowski SA et al (2008) A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene 27:1019-1032 (Pubitemid 351225390)
47. Thomas C, Gustafsson JA (2011) The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 11:597-608
48. Madeira M, Mattar A, Logullo AF, Soares FA, Gebrim LH (2013) Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer 13:425
49. Wyld DK, Chester JD, Perren TJ (1998) Endocrine aspects of the clinical management of breast cancer-current issues. Endocr Relat Cancer 5:97-110 (Pubitemid 28298656)
50. Chen S, Bangaru ML, Sneade L et al (2009) Epidermal growth factor receptor cross-talks with ligand-occupied estrogen recep-tor- alpha to modulate both lactotroph proliferation and prolactin gene expression. Am J Physiol Endocrinol Metab 297:331-339